Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib, Pembrolizumab and Trastuzumab in Advanced HER2-positive Breast Cancer
NCT04789096Phase 2Terminated
- Sponsor
- Breast Cancer Trials
- Start
- Mar 2023
- Primary completion
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucatinib, pembrolizumab in HER2-positive breast cancer, sponsored by Breast Cancer Trials. Started Mar 2023; status: terminated.
02
Drugs
tucatinibpembrolizumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04789096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04789096.